Project Grant R41CA310186
Award Date 9/19/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38103, USA
Similar Awards
- The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $392,695 project grant to Pearl Scientific Inc. in Denver, CO. The grant will fund research to develop and validate humanized Semaphorin 7A (SEMA7A)-antagonist monoclonal antibodies (mAbs) for the therapeutic treatment of breast cancer. This includes identifying high-affinity SEMA7A-antagonist mAbs, characterizing their efficacy in blocking SEMA7A-mediated tumor growth mechanisms,...
- The federal Project Grant award of $400,000.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to Promilead, LLC in South Carolina. The grant is focused on "Activating TFEB to Enhance the Efficacy of Immunotherapy for Triple Negative Breast Cancer". The key products or services to be delivered through this research grant include investigating novel strategies to improve the response of triple negative breast cancer...
- This federal Project Grant award of $1,056,000.00 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York to overcome resistance to targeted therapies in breast cancer. The research aims to elucidate the mechanisms of cancer cell plasticity and therapy resistance, focusing on the roles of genomic instability, effector pathways, and long-term response to targeted treatments. Through a...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), aims to elucidate the comprehensive mechanism by which metastatic breast cancer induces permeability of the blood-brain barrier, thereby facilitating breast cancer brain metastases (BCBM). The $479,591 award, with a period of performance from March 1, 2025 to February 28, 2030, will be performed by the University of Illinois in Chicago. Key aspects of the research include...
- This $102,984 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides funding to The Trustees of Columbia University in the City of New York to conduct research on brain metastasis progression. The key products and services to be delivered include: Performing spatiotemporal analyses of the entire brain metastasis progression arc, from single cells interacting with the blood-brain barrier to fully developed brain metastases. This will utilize novel...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $470,567 to Beth Israel Deaconess Medical Center, Inc. to identify molecular features that may make metastatic breast cancer patients responsive or resistant to PARP-inhibitor treatment, even in the absence of germline BRCA1/2 mutations. The research will analyze pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA in collaboration with the Broad Institute, building...
- This federal Project Grant award of $1,379,442.00 was provided by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to Embiosys Inc. located in North Andover, MA. The funding supports the development and evaluation of a novel wearable, washable garment (camisole/tank-top) that delivers an induced electric field (IEF) therapy, a non-ionizing electromagnetic radiation treatment targeting triple-negative breast cancer (TNBC). Preclinical TNBC mouse...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $552,763 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on KAT6A as a novel therapeutic target for the treatment of high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). The research aims to characterize the epigenetic changes induced by KAT6 inhibitors,...
- This $353,009 Project Grant awarded by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel multivalent PSMA-targeted taxane-conjugate therapeutics for treating bone metastases in prostate cancer. The primary awardee, Paramita Therapeutics Inc., a small disadvantaged business located in San Diego, California, will synthesize and evaluate these targeted drug-conjugates, which aim to selectively deliver taxane...
- This $1,634,811 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the drug development of RK-33 for the treatment of triple-negative breast cancers (TNBCs) by Natsar Pharmaceuticals, Inc. The goal is to commercialize RK-33, a small molecule inhibitor of the DDX3 RNA helicase, which has shown robust killing of TNBC cancer cells and reduced metastatic load in preclinical models. The 2-year award period runs from September 2025 through...